NYSE · LH
Healthcare · Medical - Equipment & Services
$361.39
Down-$6.77 (-1.84%)
Updated Nov 1, 2026, 1:38 PM
SID Score
7.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance · LH
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
LH closed at $361.39 after 20 trading sessions, up 17.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $370.00 | $370.97 | $358.73 | $361.39 | 773.39K |
| Oct 29, 2026 | $355.94 | $368.35 | $351.585 | $368.16 | 1.14M |
| Oct 28, 2026 | $344.55 | $371.00 | $341.40 | $360.25 | 1.8M |
| Oct 27, 2026 | $330.26 | $332.34 | $326.32 | $331.17 | 799.6K |
| Oct 26, 2026 | $329.77 | $331.76 | $327.0701 | $329.90 | 653.78K |
| Oct 23, 2026 | $327.09 | $331.565 | $326.8301 | $328.95 | 663.98K |
| Oct 22, 2026 | $320.20 | $331.71 | $314.78 | $329.93 | 961.98K |
| Oct 21, 2026 | $319.10 | $325.00 | $317.71 | $323.75 | 566.73K |
| Oct 20, 2026 | $321.10 | $324.50 | $317.96 | $323.13 | 591.77K |
| Oct 19, 2026 | $316.54 | $320.00 | $314.685 | $318.83 | 650.19K |
| Oct 16, 2026 | $326.05 | $327.50 | $316.12 | $317.95 | 705.99K |
| Oct 15, 2026 | $321.60 | $325.15 | $320.22 | $325.07 | 542.03K |
| Oct 14, 2026 | $314.10 | $319.75 | $314.10 | $317.34 | 573.57K |
| Oct 13, 2026 | $316.70 | $319.30 | $312.22 | $313.64 | 453.84K |
| Oct 12, 2026 | $310.11 | $316.75 | $310.11 | $315.52 | 405.31K |
| Oct 9, 2026 | $313.39 | $318.175 | $311.62 | $312.15 | 607.87K |
| Oct 8, 2026 | $312.34 | $315.48 | $309.04 | $314.20 | 703.73K |
| Oct 7, 2026 | $312.04 | $315.085 | $311.21 | $311.97 | 546.62K |
| Oct 6, 2026 | $310.41 | $312.7551 | $304.92 | $311.71 | 987.79K |
| Oct 5, 2026 | $308.08 | $309.785 | $305.84 | $308.65 | 705.91K |
The latest Smart Investors Daily articles mentioning LH.
Company
Market Activity
Research & News
LH research
Company profile and research snapshot.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Truist Securities | Buy | — |
| Oct 29, 2026 | Barclays | Equal-Weight | — |
| Oct 29, 2026 | UBS | Buy | — |
| Oct 29, 2026 | Baird | Outperform | — |
| Sep 21, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Yahoo · Oct 30, 2026
Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash flows the business can generate, or has enthusiasm run ahead of what those cash streams can reasonably support? Over the past 3 years the stock has returned 115.3%, which puts real pressure on the idea that the present valuation is still aligned with what the underlying cash...
Yahoo · Oct 30, 2026
The fair value estimate for Labcorp Holdings has been adjusted from US$344.25 to US$354.50, a move of about US$10.25 that reflects updated analyst work after the latest Q3 review. External analysts have gone further, with several price targets now between US$380 and US$410, which shows a wider debate around how much upside Labcorp Holdings might support if current assumptions hold. In the sections that follow, you will see how to interpret these shifting targets and track the evolving story...
Yahoo · Oct 29, 2026
Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network. The BD Onclarity HPV Assay rollout is designed to broaden access to advanced cervical cancer screening for patients across the United States. Labcorp announced a collaboration with the FDA and Charles River Laboratories to refine methods used to evaluate drug abuse potential. These moves on BD Onclarity HPV testing and drug abuse potential assessment only...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LH.
